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Abstract
Purposes: The aim of this study was to analyse how well FRAXH predicts the risk of major osteoporotic and vertebral
fractures over 6 years in postmenopausal women from general population.
Patients and methods: The OPUS study was conducted in European women aged above 55 years, recruited in 5 centers
from random population samples and followed over 6 years. The population for this study consisted of 1748 women (mean
age 74.2 years) with information on incident fractures. 742 (43.1%) had a prevalent fracture; 769 (44%) and 155 (8.9%) of
them received an antiosteoporotic treatment before and during the study respectively. We compared FRAXH performance
with and without bone mineral density (BMD) using receiver operator characteristic (ROC) c-statistical analysis with ORs and
areas under receiver operating characteristics curves (AUCs) and net reclassification improvement (NRI).
Results: 85 (4.9%) patients had incident major fractures over 6 years. FRAXH with and without BMD predicted these
fractures with an AUC of 0.66 and 0.62 respectively. The AUC were 0.60, 0.66, 0.69 for history of low trauma fracture alone,
age and femoral neck (FN) BMD and combination of the 3 clinical risk factors, respectively. FRAXH with and without BMD
predicted incident radiographic vertebral fracture (n = 65) with an AUC of 0.67 and 0.65 respectively. NRI analysis showed a
significant improvement in risk assignment when BMD is added to FRAXH.
Conclusions: This study shows that FRAXH with BMD and to a lesser extent also without FN BMD predict major osteoporotic
and vertebral fractures in the general population.
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Introduction
Bone mineral density (BMD) measurement by dual x-ray
absorptiometry (DXA) is regarded as the reference method for
fracture prediction [1,2]. However, BMD explains only a part of
an individual’s fracture risk because of the multiple determinants
of fragility fracture [3]. Studies have shown that up to one half of
patients with incident fractures have baseline BMD above the
diagnostic threshold of osteoporosis T score #22.5 [4,5]. Thus
attention must be paid to the identification of subjects at high risk
of fracture, and many clinical risk factors predict the risk of
fracture, independently of the BMD. The combination of BMD
with risk factors can improve the detection of patients at high risk
of osteoporotic fractures [6–12], including non vertebral [13–17],
and vertebral fractures [17–23]. To identify persons at high risk for
hip fracture and other fractures associated with osteoporosis, the
WHO developed two 10-yr probabilities of fracture models
(FRAXH): one for hip fracture and one for major osteoporotic
fracture (hip, spine [clinical], wrist, or shoulder). FRAXH uses nine
clinical risk factors to estimate the 10-yr probability of fracture:
age, sex, body mass index, parental history of hip fracture,
exposure to systemic glucocorticoı¨ds, history of prior fragility
fracture, current smoking, three or more units of alcohol per day,
and the presence of secondary osteoporosis [24]. The validity of
the WHO 10-yr probability of major osteoporotic fracture model
(FRAXH) for prediction of fracture has been tested in some studies
[24–30]. The National Osteoporosis Foundation recommendation
is to use FRAXH only when the decision to treat or not to treat is
difficult, i.e. mainly in postmenopausal women without osteopo-
rosis and without prevalent fracture [31]. The Osteoporosis and
Ultrasound Study (OPUS) is thus an appropriate population in
which to assess the predictive value of FRAXH, as participants
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were postmenopausal women recruited from the general popula-
tion, and thus were without referral bias. We analyzed how well
FRAXH with and without femoral neck BMD (FN BMD),
predicted the risk of incident major osteoporotic and vertebral
fractures over 6 years in the OPUS cohort conducted in European
postmenopausal women.
Patients and Methods
Patients
The Osteoporosis and Ultrasound Study (OPUS) is a multicen-
ter prospective study of risk factors for fractures in post
menopausal women. Both the rationale and the study design have
been described in details elsewhere [32]. The initial study
population consisted of 2409 ambulatory European women aged
above 55 years, recruited in 5 European centers from random
population samples between 1999 and 2001, and followed for 6
years. Women were excluded if they had disorders precluding
ultrasound and bone mineral density measurements, and also
general and cognitive inability that precluded completing ques-
tionnaire.
For this study, we included 1748 women with information on
incident major osteoporotic fractures. The first outcome was the
incident major osteoporotic fractures as defined by FRAXH. The
secondary outcome was the incidence of radiographic incident
vertebral fractures. We analysed the predictive value of FRAXH in
the whole population and in a subgroup of 698 patients who had
never been treated before or during the study, as it is
recommended to use FRAXH only in untreated individuals [24].
Ethics Statement
Human subjects review or ethics committees at each partici-
pating institution (‘‘Ethikkommission der Medizinischen Fakulta¨t
der Christian-Albrechts-Universita¨t zu Kiel’’ for Kiel, ‘‘Ethikkom-
mission des Universita¨tsklinikum Benjamin Franklin der Freien
Universita¨t Berlin’’ for Berlin, ‘‘North Sheffield Research Ethics
Committee’’ for Sheffield, ‘‘North of Scotland Research Ethics
Committee, Grampian Health Board’’ for Aberdeen and ‘‘Comite´
consultatif de protection des personnes (CCPPRB) Paris-Cochin’’
for Paris) reviewed and approved the study. Written informed
consent was obtained from all participants.
Assessment of risk factors of FRAXH and calculation of
FRAXH tool
All risk factors for fracture included in FRAXH were assessed
baseline. Among the secondary osteoporosis categories in FRAXH,
data on type 1 diabetes, osteogenesis imperfecta and chronic liver
disease were not available. Prior non vertebral fractures were those
that occurred after the age of 50 years, identified by self-reporting
during the baseline questionnaire.
Bone mineral density of the lumbar spine and of the proximal
femur was measured using dual energy X-ray absorptiometry
(DXA) in the postero-anterior projection (Hologic QDR-4500;
Hologic, Bedford, MA, USA in Paris, Kiel and Sheffield centers)
or in the antero-posterior (Lunar Expert devices; GE Lunar,
Madison, USA in the Berlin and Aberdeen centers) using
standardised procedures and centralised quality control.
FRAXH was calculated by the WHO collaborating centre for
Metabolic Bone Diseases, University of Sheffield, UK, using
country-specific data. We used the FRAXH estimate of major
osteoporotic fracture (including clinical spine fractures) in all
analyses. Our model is conditional on the estimates of the 10-yr
probability of fracture developed by FRAXH.
Fracture assessment
Self-reports of incident fractures were confirmed by written
reports of radiographs or surgical reports. We excluded pathologic
fractures. A major osteoporotic fracture was defined as a fracture
of the hip, spine (clinical), wrist, or humerus. Clinical vertebral
fractures were defined as those that came to medical attention and
were reported to the clinical centers by the participants. A copy of
the radiograph obtained by the patient’s physician was sent to the
coordinating center and compared with the baseline study
radiograph.
Vertebral fracture status was determined on lumbar and
thoracic spine radiographs performed using a standardized
procedure identical in all centers, and a standardized assessment
in a central facility in the Berlin center. Radiographs were
performed at baseline and final 6-year visits using the same
procedures, and evaluated centrally by two radiologists. The
procedure to assess fracture status combined morphometric
measurements of vertebral heights and the qualitative interpreta-
tion of fracture status: vertebrae with deformities of non-
osteoporotic origin (degenerative changes) or exhibiting potential
misleading appearances were not considered as fracture. For both
prevalent and incident deformities a decrease of at least 20% of
any height or height ratio was considered for the diagnosis of
fracture.
Statistical analysis
The characteristics of women with and without incident major
osteoporotic fractures were compared by using chi-square tests or
Fisher’s exact tests, or t-tests as appropriate.
We assessed the association between age, femoral neck (FN)
BMD, history of low trauma fracture and combination of these
factors. We tested the association of FRAXH with and without FN
BMD. We used logistic regression to calculate the OR and 95%
CI. We used the C-statistic and 95% CI to evaluate the
discrimination of each model. The C-statistic estimates the area
under the receiver operator characteristic (ROC) curve (AUC) and
indicates the model’s ability to distinguish those with and without
incident major osteoporotic fractures and incident radiographic
vertebral fractures. We analysed the predictive value of FRAXH in
the whole population (n = 1748) and in the population who never
received any anti-osteoporotic treatment (n = 698) and who ever
received antiosteoporotic treatment (n = 1050).
Reassignment was evaluated by net reclassification improve-
ment [33–34]. The NRI evaluates the movement of individuals
between risk categories from one model to another. First, among
those who fracture, the proportion moving upward from low-risk
to high-risk category is subtracted from the proportion moving
downward from high-risk to low-risk category. Second, among
those who remain free of fracture, the proportion moving upward
from low-risk to high-risk category is subtracted from the
proportion moving downward from high-risk to low-risk category.
Finally, 2 differences are summed; the higher the value, the more
appropriate the reassignments. For this analysis, we determined 3
categories of risk using 2 thresholds. The first cut point was
determined using the ROC threshold that gave the maximum
Younden’s Index [35]. (equal to the sensitivity plus the specificity
minus 1) which corresponded to 3.5% 10-yr major osteoporotic
fracture probability in the model with BMD. The second cut point
was the clinical treatment threshold of 20% for major osteoporotic
fractures proposed by the National Osteoporosis Foundation
(NOF) [36].
Statistics were performed using Statistical Analysis Software
(SAS V9.1, SAS Institute, Cary, NC, USA).
Prediction of Major Fractures Using FRAXH
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Results
A group of 1748 women is the basis of this study, and their
baseline characteristics are in the Table 1. Participants were
followed from 4.5 years to 7.5 years (mean 6.04 years). 85 (4.9%)
patients with incident major osteoporotic fractures were recorded
including 9 patients with hip fractures; 65 (4.2%) patients with
incident radiographic vertebral fractures were recorded. In
patients with a history of low trauma fracture (n = 742, 43.1%),
the incidence rate of major osteoporotic fracture and radiographic
vertebral fractures were 6.7% and 5.0% respectively.
According to the inclusion criteria in OPUS, baseline mean T
scores (6SD) were in the normal range at both the lumbar spine
and the femoral neck (20.9561.53 and 20.4261.05, respective-
ly). The mean FRAXH value was 13.03 6 8.52%.
Prediction of the risk of incident major osteoporotic
fractures in the whole population
Patients with incident major osteoporotic fractures were older,
reported more frequently history of low trauma fracture and of
prevalent radiographic vertebral fracture and had a significant
lower baseline femoral neck BMD than patients without incident
major osteoporotic fractures (Table 1).
In the table 1b are reported the baseline parameters associated
with incident major osteoporotic fracture over 6 years. The AUCs
are reported in table 2 and depicted in Figure 1. The highest AUC
was observed for the combination of age, femoral neck BMD and
previous history of fracture, which was significantly higher than
the AUC for FRAXH without BMD (p#0.0001) and for FRAXH
with BMD (p = 0.021). The AUC for FRAXH with BMD was
higher than the AUC for FRAXH without BMD (0.66 vs 0.62,
p = 0.012). 8.3% of patients had a FRAXH with BMD $20% and
20.3% with incident fracture had a FRAXH with BMD $20%.
Using reassignment analysis, we examined the differences
between FRAXH models estimates with and without BMD using
3 categories of risk 0,3.5%, 3.5–#19%, and$20% (Table 3). We
calculated the NRI to be 10.6% (p = 0.032), indicating a
statistically significant improvement in risk assignment when
BMD was added to the model. We also compared the differences
between FRAXH model with BMD and the combination age,
femoral neck BMD and previous history of fracture; the NRI was
2.4% (p = 0.711) indicating the absence of improvement risk
assignment when the combination age, femoral neck BMD and
previous was used.
Table 1. Baseline characteristics of the whole population with and without incident major osteoporotic fractures during the
follow-up (n = 1748).
Whole population No incident fracture Incident fracture P value
N (%) 1748 1663 (95.1) 85 (4.9)
Age (years) (mean±SD) 66.1 (6.8) 66.0 (6.7) 68.5 (7.4) 0.002
Baseline lumbar spine T score, (mean ±SD) 20.95 (1.53) 20.94 (1.54) 21.33 (1.25) 0.055
Baseline femoral neck T score, (mean±SD) 20.42 (1.05) 20.41 (1.05) 20.79 (0.98) 0.028
Prevalent radiographic vertebral fractures N (%) 219 (12.5) 197 (11.9) 22 (25.9) 0.0001
FRAX clinical risk factors
History of low trauma fracture N (%) 742 (43.1) 692 (42.1) 50 (61.7) 0.001
BMI, (mean 6SD) 26.7 (4.5) 26.7 (4.5) 27.3 (3.9) 0.049
Parental history of hip fracture N, (%) 180 (10.5) 166 (10.2) 14 (18.2) 0.025
History of exposure to systemic glucocorticoids (%) 45 (2.7) 43 (2.7) 2 (2.5) 1.000
Rheumatoid arthritis (%) 108 (6.4) 102 (6.4) 6 (7.8) 0.631
Current smoking N (%) 236 (13.8) 222 (13.6) 14 (17.5) 0.328
Alcohol ($ 3 units/day) N (%) 11 (0.6) 11 (0.7) 0 (0.0) 1.000
Secondary osteoporosis N (%) 521 (30.2) 500 (30.4) 21 (25.) 0.392
Type 1 diabetes, _ _ _ _
Osteogenesis Imperfecta _ _ _ _
Malnutrition 150 (9.8) 140 (9.6) 10 (13.9) 0.228
Malabsorption 7 (0.5) 7 (0.4) 0 (0) 1.000
Hypogonadism, 59 (3.8) 53 (3.6) 6 (8.2) 0.057
Menopause before 45 years 310 (20.0) 293 (19.8) 17 (23.3) 0.466
Untreated Hyperthyroidism 49 (3.3) 48 (3.4) 1 (1.4) 0.725
FRAX 10-yr risk (%) of [mean (SD)]
Osteoporotic fracture, without BMD 13.03 (8.52) 12.88 (8.46) 16.18 (9.18) 0.001
Osteoporotic fracture, with BMD 10.23 (7.02) 10.05 (6.84) 14.38 (9.47) ,.0001
Proportion of patients treated N (%)
Before and/or during the follow-up 1050 (60) 1000 (60.1) 50 (58.8) 0.810
During the study 155 (8.9) 136 (8.2) 19 (22.4) ,.0001
doi:10.1371/journal.pone.0083436.t001
Prediction of Major Fractures Using FRAXH
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e83436
Prediction of the risk of incident radiographic vertebral
fractures in the whole population
Data were available in 1554 patients. Patients with incident
vertebral radiographic fractures reported more frequently a history
of prevalent radiographic vertebral fracture and of low trauma
fracture, and had a significant lower baseline femoral neck BMD
than patients without incident radiographic vertebral fractures
(Table 4).
In the table 2b are reported the baseline parameters associated
with incident radiographic vertebral fracture over 6 years. The
AUCs are reported in table 5 and in Figure 2. The highest AUC
was observed for the combination of age, femoral neck BMD and
baseline radiographic vertebral fracture, which was significantly
higher than the AUC for FRAXH without BMD (p = 0.013) and
for FRAXH with BMD (p = 0.005). The AUC for FRAXH with
BMD was similar to the AUC for FRAXH without BMD (0.67 vs
0.65, p = 0.204).
8.3% of patients had a MOF-FRAXH with BMD$20% and
24.6% with incident radiographic vertebral fracture had a FRAXH
with BMD$20%. Reassignment analysis did not show significant
improvement when BMD was added to FRAX without BMD or
when the combination of age, femoral neck BMD and baseline
radiographic vertebral fracture was used (data not shown).
Prediction of the risk of incident major osteoporotic
fracture in the subpopulation of postmenopausal
women who never received any anti-osteoporotic
treatment (n = 698)
Characteristics of those patients are summarized in Table 6 and
were similar to those of the general population. In this
subpopulation (n = 698), femoral neck BMD, history of low
trauma fracture and the combination of age, femoral neck BMD
and history of low trauma fractures were still predictors of incident
major osteoporotic fractures OR = 1.61 (1.08–2.40) (AUC =
Figure 1. ROC curves for models to predict women with incident major osteoporotic fractures in the whole population.
doi:10.1371/journal.pone.0083436.g001
Table 2. Summary statistics for models to predict women with incident major osteoporotic fracture in the whole population.
Model OR/SD (95%CI) C-statistic (95%)
Age 1.43 [1.15 – 1.78] 0.60 [0.53 – 0.66]
FN BMD 1.80 [1.40 – 2.34] 0.65 [0.58 – 0.71]
History of low trauma fracture 1.48 [1.19 – 1.87] 0.60 [0.54 – 0.65]
Prevalent radiographic VF 1.37 [1.15 – 1.62] 0.57 [0.52 – 0.62]
FN BMD + age 1.57 [1.31 – 1.88] 0.66 [0.60 – 0.72]
FN BMD + age+ history of low trauma fracture 1.61 [1.34 – 1.92] 0.69 [0.63 – 0.75]
Baseline radiographic VF+ FN BMD + age 1.55 [1.31 – 1.81] 0.68 [0.61 – 0.74]
FRAX without FN BMD 1.37 [1.12 – 1.67] 0.62 [0.56 – 0.68]
FRAX with FN BMD 1.50 [1.26 – 1.77] 0.66 [0.60 – 0.73]
doi:10.1371/journal.pone.0083436.t002
Prediction of Major Fractures Using FRAXH
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0.58), OR = 1.42 (1.09–1.81) (AUC = 0.65) and OR = 1.48 (1.00–
2.13) (AUC = 0.70) respectively) (Table 7). FRAXH with and
without BMD was not a predictor of incident major osteoporotic
fractures OR = 1.33 (0.95–1.79) and OR = 1.27 (0.88–1.77)
respectively.
Prediction of the risk of incident major osteoporotic
fracture in the subpopulation of postmenopausal
women who ever received any anti-osteoporotic
treatment (n = 1050)
Characteristics of those patients are summarized in Table 8 and
were similar to those of the general population. In this
subpopulation (n = 1050), femoral neck BMD, history of low
trauma fracture and the combination of age, femoral neck BMD
and prevalent radiographic vertebral fracture were predictors of
incident major osteoporotic fractures OR = 1.59 (1.22 – 2.07)
(AUC = 0.64), OR = 1.95 (1.40 – 2.76) (AUC = 0.69) and
OR = 2.33 (1.21 – 4.50) (AUC = 0.57) respectively) (Table 9).
FRAXH with and without BMD were predictors of incident major
osteoporotic fractures (OR = 1.43 (1.12 – 1.80) (AUC = 0.66) and
(OR = 1.58 (1.28 – 1.94) (AUC = 0.70) without any difference.
Table 3. Fracture risk stratification, by calculated 10-year risks
of major osteoporotic fracture from FRAXH models with and
without BMD.
Model with BMD Model without BMD Total
Frequency (Row per
cent)
, 3.5% $3.5 and
#19%
$ 20%
Patients with fracture
, 3.5% 13 (68.4%) 6 (31.6%) 0 (0.0%) 19
$3.5 and #19% 2 (4.3%) 45 (95.7%) 0 (0.0%) 47
$ 20% 0 (0.0%) 3 (100.0%) 0 (0.0%) 3
Total 15 54 0 69
Patients without fracture
, 3.5% 522 (69.3%) 231 (30.7%) 0 (0.0%) 753
$3.5 and #19% 44 (5.7%) 726 (94.3%) 0 (0.0%) 770
$ 20% 0 (0.0%) 3 (75.0%) 1 (25.0%) 4
Total 566 960 1 1527
doi:10.1371/journal.pone.0083436.t003
Table 4. Baseline characteristics of women in the whole population who had at least one radiographic vertebral fracture during
follow-up and those who did not (n = 1554).
No incident fracture Incident fracture P value
N (%) 1489 (95.8) 65 (4.2)
Age (years) (mean±SD) 65.5 (6.6) 69.4 (6.7) ,0.0001
Baseline lumbar spine T score (mean ±SD) 20.93 (1.52) 21.43 (1.31) 0.039
Baseline femoral neck T score (mean±SD) 20.38 (1.05) 20.90 (1.01) 0.001
Prevalent radiographic vertebral fractures N (%) 164 (11.0) 27 (41.5) ,.0001
FRAX clinical risk factors
History of low trauma fracture N (%) 613 (41.8%) 37 (57.8%) 0.011
BMI, (mean 6SD) 26.6 (4.4) 25.9 (4.3) 0.168
Parental history of hip fracture N, (%) 154 (10.6) 10 (15.6) 0.206
History of exposure to systemic glucocorticoı¨ds (%) 32 (2.2) 1 (1.6) 1.000
Rheumatoid arthritis (%) 82 (5.7) 5 (7.9) 0.410
Current smoking N (%) 186 (12.8) 11 (17.2) 0.310
Alcohol ($ 3 units/day) N (%) 8 (0.6) 1 (1.6) 0.322
Secondary osteoporosis N (%) 431 (29.4) 16 (25.0) 0.453
Type 1 diabetes, _ _ _
Osteogenesis Imperfecta, _ _ _
Malnutrition 139 (9.6) 10 (15.4) 0.125
Malabsorption 7 (0.5) 0 (0) 1.000
Hypogonadism, 56 (3.9) 2 (3.1) 1.000
Menopause before 45 years 296 (20.2) 12 (18.5) 0.732
Untreated Hyperthyroidism 45 (3.2) 1 (1.6) 1.000
FRAX 10-yr risk (%) of [mean (SD)]
Osteoporotic fracture, without BMD 12.3 (8.1) 17.2 (11.3) 0.0001
Osteoporotic fracture, with BMD 9.6 (6.7) 14.7 (11.2) ,.0001
Proportion of patients treated N (%)
In the past 907 (61.1) 46 (70.8) 0.112
At baseline and/over the follow-up 124 (8.3) 23 (35.4) ,.0001
doi:10.1371/journal.pone.0083436.t004
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Discussion
This study shows that FRAXH with and without FN BMD can
predict incident major osteoporotic over 6 years in European
postmenopausal women recruited from general population. In this
population which included proportion of women who had been
treated by anti-osteoporotic treatment in past or who were treated
during the follow-up, ROC c-statistical analysis showed that the
performance of FRAXH with FN BMD was better than that of
FRAXH without FN BMD. Because of the limitations of ROC
analysis, reassignment analysis which has been proposed as a novel
method to evaluate fracture risk models confirmed that the
addition of BMD to FRAXH significantly increases the prediction,
supporting results of previous studies [36]. Using ROC c-statistic
analysis, the combination of FN BMD, age and self-reported
fracture history significantly predicted incident major osteoporotic
fractures with a higher predictive value than FRAXH with BMD.
However, these results were not confirmed by the reassignment
analysis.
In postmenopausal women who never received any anti-
osteoporotic treatment, FRAXH with and without BMD was not
a predictor of incident major osteoporotic fractures; however
interpretation of the results is largely limited by the small number
of women never treated. In women who ever received an anti-
osteoporotic treatment, we confirmed that FRAXH with and
without BMD can be used in patients currently or previously
treated for osteoporosis [37]. However, FRAXH should not be
used to assess the reduction in fracture risk in individuals on
treatment.
The performance characteristics of the FRAXH tool have been
validated in independent cohorts from various countries [24] with
over a million of person-years of observation. Previous studies
conducted in population with past/current osteoporotic treatment
[30,38,39] and without such treatment [26,40] reported the
prediction of FRAXH in elderly women [30,38,39,40] and in peri-
and early postmenopausal women [26]. Using data of the SOF
(Study of Osteoporotic Study) study, a cohort of older community-
dwelling women (n = 6252, mean age of 71.3 years), Ensrud et al
Figure 2. ROC curves for models to predict women with at Least One incident radiographic vertebral fracture.
doi:10.1371/journal.pone.0083436.g002
Table 5. Summary statistics for models to predict women with at least one radiographically detected Vertebral Fracture.
Model OR/SD (95%CI) C-statistic (95%)
Age 1.77 [1.38 – 2.27] 0.66 [0.60 – 0.73]
FN BMD 1.87 [1.43 – 2.47] 0.67 [0.60 – 0.74]
History of low trauma fracture 1.38 [1.07 – 1.77] 0.58 [0.52 – 0.64]
Prevalent radiographic VF 1.78 [1.49 – 2.10] 0.65 [0.59 – 0.71]
FN BMD + age 1.64 [1.37 – 1.96] 0.69 [0.63 – 0.76]
FN BMD + age+ history of low trauma fracture 1.67 [1.39 – 1.99] 0.70 [0.63 – 0.77]
Baseline radiographic VF+ FN BMD + age 1.80 [1.56 – 2.09] 0.73 [0.66 – 0.80]
FRAX without FN BMD 1.57 [1.28 – 1.91] 0.65 [0.58 – 0.71]
FRAX with FN BMD 1.55 [1.30 – 1.84] 0.67 [0.60 – 0.73]
doi:10.1371/journal.pone.0083436.t005
Prediction of Major Fractures Using FRAXH
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showed that a simple model based on age and BMD predicted 10-
year risk of hip, major osteoporotic, and any clinical fracture as
well as FRAXH models with BMD [30]. In the MENOS study
(mean age 5464 years) included 2,651 women (exclusion of
women with past/current osteoporosis treatment. 3 months at
baseline (n = 455) with a mean follow-up period of 13.4 years
(61.4 years), only a limited number of clinical risk factors were
found to be associated with the risk of major OP fracture. In this
population as in our study, the FRAXH did not significantly
improve the discriminatory value of femur BMD alone [26].
The FRAXH tool is not designed to examine the risk of
radiographic vertebral fractures; however we performed this
exploratory analysis because of the importance of vertebral
fractures in the outcome of osteoporosis, and because OPUS
design gives the opportunity to assess that, as vertebral fractures
were assessed on radiographs performed with standardized
Table 6. Baseline characteristics of women who never received any treatment with (n = 663) and without incident major
osteoporotic fractures (35) during the follow-up (n = 698).
Women untreated No incident fracture Incident fracture P value
N (%) 698 (39.9) 663 (95.0) 35 (5.0) _
Age (years) (mean±SD) 69.1 (6.4) 69.0 (6.3) 70.3 (8.1) 0.162
Baseline lumbar spine T score (mean ±SD) 20.90 (1.44) 20.89 (1.45) 21.00 (1.35) 0.912
Baseline femoral neck T score, (mean±SD) 20.42 (1.03) 20.41 (1.03) 20.76 (0.92) 0.272
Prevalent radiographic vertebral fractures N (%) 75 (10.7) 66 (10.0) 9 (25.7) 0.008
FRAX clinical risk factors
History of low trauma fracture N (%) 286 (42.1) 263 (40.7) 23 (69.7) 0.001
BMI, (mean 6SD) 27.5 (4.6) 27.5 (4.7) 27.5 (3.9) 0.718
Parental history of hip fracture N, (%) 59 (8.8) 56 (8.7) 3 (9.4) 0.754
History of exposure to systemic glucocorticoids (%) 10 (1.5) 9 (1.4) 1 (3.2) 0.381
Rheumatoid arthritis (%) 48 (7.3) 43 (6.9) 5 (16.1) 0.067
Current smoking N (%) 80 (11.9) 76 (11.8) 4 (12.5) 0.784
Alcohol ($ 3 units/day) N (%) 3 (0.4) 3 (0.5) 0 (0.0) 1.000
Secondary osteoporosis N (%) 214 (31.5) 207 (32.0) 7 (21.2) 0.249
Type 1 diabetes, _ _ _ 0.513
Osteogenesis Imperfecta, _ _ _ _
Malnutrition, 57 (9.7) 53 (9.5) 4 (13.8)
Malabsorption, 2 (0.3) 2 (0.4) 0 (0.0) 0.079
Hypogonadism, 21 (3.6) 18 (3.2) 3 (10.3) -
Menopause before 45 years 119 (20.0) 116 (20.5) 3 (10.3) 0.184
Untreated Hyperthyroidism 17 (3.0) 16 (2.9) 1 (3.6) 0.577
FRAX 10-yr risk (%) of [mean (SD)]
Osteoporotic fracture, without BMD 14.75 (8.21) 14.65 (8.12) 16.82 (9.85) 0.280
Osteoporotic fracture, with BMD 11.09 (6.16) 10.99 (6.08) 13.16 (7.44) 0.155
doi:10.1371/journal.pone.0083436.t006
Table 7. Summary Statistics for Models to Predict Women with at Least One major osteoporotic fracture and who never received
any antiosteoporotic.
Model OR/SD (95%CI) C-statistic (95%)
Age 1.23 [0.87 – 1.76] 0.57 [0.45 – 0.69]
FN BMD 1.61 [1.08 – 2.40] 0.58 [0.47 – 0.69]
History of low trauma fracture 1.42 [1.09 – 1.81] 0.65 [0.56 – 0.73]
Prevalent radiographic VF 1.04 [0.69 – 1.60] 0.58 [0.51 – 0.65]
FN BMD + age 1.35 [0.92 – 1.87] 0.59 [0.47 – 0.70]
FN BMD + age+ history of low trauma fracture 1.48 [1.00 – 2.13] 0.70 [0.61 – 0.78]
Baseline radiographic VF+ FN BMD + age 1.61 [1.21 – 2.10] 0.61 [0.50 – 0.73]
FRAX without FN BMD 1.27 [0.88 – 1.77] 0.56 [0.45 – 0.68]
FRAX with FN BMD 1.33 [0.95 – 1.79] 0.58 [0.47 – 0.70]
doi:10.1371/journal.pone.0083436.t007
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procedures of acquisition, by experts in a central facility, and
without a context of clinical study conducted in an osteoporotic
population. In this cohort of postmenopausal women (mean age
65.5 years), of whom 12.5% had a radiographically detected
vertebral fracture at baseline and a mean lumbar spine of 20.95,
FRAXH with and without BMD discriminate patients with
incident radiographic vertebral fractures. Our study shows that
the strongest risk factor of future vertebral fracture was the
combination of age, femoral neck BMD and the presence of a
radiographic vertebral fracture at baseline. There is only one
previous study which analyses the predictive value of FRAXH for
incident radiographic vertebral fractures. It was conducted in 3321
post-menopausal women with low bone mass (60% of them having
a femoral neck T score #22.5) from the FIT (Fracture
Intervention Trial) placebo group, of whom 30% had a
radiographically detected vertebral fracture at baseline. FRAXH
Table 8. Baseline characteristics of women who ever received antiosteoporotic treatment t with (n = 50) and without incident
major osteoporotic fractures (n = 1000) during the follow-up (n = 1050).
Women treated No incident fracture Incident fracture P value
N (%) 1050 (60.1) 1000 (95.2) 50 (4.8) _
Age (years) (mean±SD) 64.1 (6.3) 64.0 (6.3) 67.2 (6.6) 0.001
Baseline lumbar spine T score (mean ±SD) 20.99 (1.58) 20.97 (1.59) 21.57 (1.12) 0.015
Baseline femoral neck T score (mean±SD) 20.83 (1.07) 20.80 (1.07) 21.57 (1.12) ,.0001
Prevalent radiographic vertebral fractures N (%) 144 (13.7) 131 (13.1) 13 (26.0) 0.010
FRAX clinical risk factors
History of low trauma fracture N (%) 456 (43.7) 429 (43.1) 27 (56.3) 0.072
BMI, (mean 6SD) 26.2 (4.3) 26.1 (4.3) 27.2 (3.9) 0.028
Parental history of hip fracture N, (%) 121 (11.7) 110 (11.1) 11 (24.4) 0.007
History of exposure to systemic glucocorticoids (%) 35 (3.4) 34 (3.5) 1 (2.1) 1.000
Rheumatoid arthritis (%) 60 (5.9) 59 (6.1) 1 (2.2) 0.515
Current smoking N (%) 156 (15.1) 146 (14.8) 10 (20.8) 0.256
Alcohol ($ 3 units/day) N (%) 8 (0.8) 8 (0.8) 0 (0.0) 1.000
Secondary osteoporosis N (%) 307 (29.4) 293 (29.4) 14 (29.2) 0.977
Type 1 diabetes, _ _ _ _
Osteogenesis Imperfecta, _ _ _ _
Malnutrition, 93 (9.8) 87 (9.6) 6 (14.0) 0.302
Malabsorption, 5 (0.5) 5 (0.6) 0 (0.0) 1.000
Hypogonadism, 38 (4.0) 35 (3.9) 3 (6.8) 0.414
Menopause before 45 years 191 (20.0) 177 (19.4) 14 (31.8) 0.044
Untreated Hyperthyroidism 32 (3.5) 32 (3.6) 0 (0.0) 0.394
FRAX 10-yr risk (%) of [mean (SD)]
Osteoporotic fracture, without BMD 11.91 (8.53) 11.74 (8.48) 15.78 (8.83) 0.0003
Osteoporotic fracture, with BMD 9.68 (7.48) 9.43 (7.22) 15.16 (10.59) ,0.0001
doi:10.1371/journal.pone.0083436.t008
Table 9. Summary Statistics for Models to Predict Women with at Least One major osteoporotic fracture and who received any
antiosteoporotic treatment.
Model OR/SD (95%CI) C-statistic (95%)
Age 1.59 [1.22 – 2.07] 0.64 [0.57 – 0.72]
FN BMD 1.95 [1.40 – 2.76] 0.69 [0.61 – 0.76]
History of low trauma fracture 1.70 [0.95 – 3.05] 0.57 [0.49 – 0.64]
Prevalent radiographic VF 2.33 [1.21 – 4.50] 0.57 [0.50 – 0.63]
FN BMD + age 1.59 [1.27 – 1.98] 0.71 [0.63 – 0.79]
FN BMD + age+ history of low trauma fracture 1.60 [1.29 – 1.99] 0.71 [0.64 – 0.79]
Baseline radiographic VF+ FN BMD + age 1.55 [1.27 – 1.89] 0.72 [0.64 – 0.80]
FRAX without FN BMD 1.43 [1.12 – 1.80] 0.66 [0.59 – 0.74]
FRAX with FN BMD 1.58 [1.28 – 1.94] 0.70 [0.63 – 0.78]
doi:10.1371/journal.pone.0083436.t009
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with and without BMD did predict vertebral fracture [27]. These
results of study are confirmed by our exploratory analysis
conducted in a population with a lower prevalence of vertebral
fractures at baseline, and a low prevalence of osteoporosis.
FRAXH has been included as a tool for identifying postmen-
opausal women in recently updated guidelines published by the
NOF in the United States [31] and by the National Osteoporosis
Guideline Group [NOGG]), in the UK [24,41]. The NOF
recommends using FRAX when the decision to treat or not to
treat is uncertain. It is primarily intended for postmenopausal
women and men 40 years of age and older who have T-scores
between 21.0 SD and 22.5 SD and who are not on treatment,
and who have not had spine or hip fractures [31]. In this general
population, our study shows that the performance of FRAXH is
mainly determined by the femoral neck BMD and previous
fragility fracture, confirming previous studies [27,30]. This lack of
accuracy of FRAXH can be explained by some limitations of this
algorithm, especially the disregard of some well established risk
factors. However these limitations can be applied to all the
prediction tools (Garvan fracture risk calculator, QF fracture)
[42,43]. The task forces of the ISCD (International Osteoporosis
Foundation) and of the IOF (International Osteoporosis Founda-
tion) recently reviewed and suggested explanations for the
limitations of FRAXH, and particularly the risk factors not
considered [44]. Falls and risk factors for falls are excluded from
the FRAXH because of the lack of standardized evaluation
methods and the lack of fracture prevention data with fall
prevention measures. Additional risk factors for fractures, such as
the number of causes of secondary osteoporosis, were not included
because of the weak evidence that they increase the risk of fracture
independently of BMD. Biochemical markers of bone turnover
were not in FRAXH because of the biological variability, the lack
of reference analytes and analytical standards [44]. An attempt to
adjust the result of FRAXH based on dose of corticosteroid has
been recently published [45].
Our study has several limitations. The first limitation concerns
the characteristics of the cohort: low rate of incident fracture, quite
short duration (6 years) of the follow-up and the significant
proportion of women previously or currently receiving bone
protective therapy which limit a lot the interpretation of the
results. Our data has been obtained in a population including
patients previously treated with anti-osteoporotic treatments. We
showed that FRAXH is a predictor of major osteoporotic fracture
in patients ever treated and not in patients never treated. We could
not confirm that the performance of FRAXH is different or not in
untreated individuals, because our sample size of untreated
subjects was too low. Other statistical analyses in subgroups of
patients ever treated and never treated as the prediction of
incident vertebral fracture and reclassification analysis were not
performed because of the low sample size of each subgroup and
the very low number of incident fractures.
Our results suggest that FRAXH with BMD performed just as
well as the combination of history of fracture, age and FN BMD.
However comparing the performance of an internally derived
model to an external predictive model provides the best predictive
performance because the internally derived model is constructed
to best fit the data within the cohort, whereas an external model is
necessarily derived from other sources.
FRAXH was not developed to predict incident radiographic
vertebral fractures; our analysis is only exploratory and our results
should be interpretated cautiously. Finally, our models are
conditional on the estimates of the 10-yr probability of fracture
developed by FRAXH.
The strengths of our study include the assessment of fracture
risk in relevant population i.e. postmenopausal women from a
random population without any selection biases. The vertebral
fractures were carefully assessed, on standardized X-rays with
central analysis. The prospective methodology of our study allows
adequate assessment of potential confounders including the main
risk factors for fractures. Moreover, we took into account the
limitations of the ROC curve methodology, criticized because they
are applied to diagnostic criteria and are not appropriate to judge
the performance of predictive algorithms [33,34]. Thus we
performed reassignment analysis using net reclassification im-
provement (NRI) [33,34] and confirmed that the addition of BMD
improved the performance of FRAXH [36]. The reassignment
analysis needs arbitrary choice of the fracture threshold; 20% for
major osteoporotic fracture is proposed by NOF and is a widely
accepted value used to estimate risk model performance. Our
study shows that the addition of BMD to FRAXH improves the
prediction of patients and could permit the careful selection of
patients who should receive the highest priority for treatment, in
order to have the better risk-benefit ratio.
In conclusion, we showed that, in a cohort of European
postmenopausal women recruited from the general population,
FRAXH can identify those at highest risk of incident major
osteoporotic fracture and incident radiographic vertebral fracture.
Different tests used to evaluate FRAX performance for prediction
of major osteoporotic fractures showed that FRAXH with BMD
performed better than FRAX without BMD.
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